AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and resp… Read more
Market Cap & Net Worth: AstraZeneca Pharma India Limited (ASTRAZEN)
AstraZeneca Pharma India Limited (NSE:ASTRAZEN) has a market capitalization of $2.44 Billion (₹211.24 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #10787 globally and #451 in its home market, demonstrating a -1.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AstraZeneca Pharma India Limited's stock price ₹8449.50 by its total outstanding shares 25000000 (25.00 Million).
AstraZeneca Pharma India Limited Market Cap History: 2015 to 2026
AstraZeneca Pharma India Limited's market capitalization history from 2015 to 2026. Data shows growth from $355.75 Million to $2.44 Billion (20.28% CAGR).
Index Memberships
AstraZeneca Pharma India Limited is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY 500
NIFTY500
|
$1.27 Trillion | 0.04% | #369 of 500 |
|
NIFTY MICROCAP 250
NIFTYMICROCAP250
|
$68.11 Billion | 0.66% | #51 of 250 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.32 Trillion | 0.03% | #387 of 750 |
|
NIFTY SMALLCAP 250
NISM250
|
$188.65 Billion | 0.24% | #154 of 250 |
Weight: AstraZeneca Pharma India Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
AstraZeneca Pharma India Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AstraZeneca Pharma India Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.15x
AstraZeneca Pharma India Limited's market cap is 0.15 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2.25x
AstraZeneca Pharma India Limited's market cap is 2.25 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $264.06 Million | $5.64 Billion | $52.59 Million | 0.05x | 5.02x |
| 2017 | $332.72 Million | $5.44 Billion | $200.50 Million | 0.06x | 1.66x |
| 2018 | $413.81 Million | $5.71 Billion | $259.10 Million | 0.07x | 1.60x |
| 2019 | $746.35 Million | $7.28 Billion | $544.50 Million | 0.10x | 1.37x |
| 2020 | $1.32 Billion | $8.32 Billion | $722.10 Million | 0.16x | 1.83x |
| 2021 | $884.82 Million | $8.09 Billion | $933.00 Million | 0.11x | 0.95x |
| 2022 | $944.20 Million | $8.06 Billion | $616.00 Million | 0.12x | 1.53x |
| 2023 | $1.59 Billion | $10.03 Billion | $992.90 Million | 0.16x | 1.60x |
| 2024 | $2.11 Billion | $12.96 Billion | $1.62 Billion | 0.16x | 1.31x |
| 2025 | $2.61 Billion | $17.16 Billion | $1.16 Billion | 0.15x | 2.25x |
Competitor Companies of ASTRAZEN by Market Capitalization
Companies near AstraZeneca Pharma India Limited in the global market cap rankings as of March 18, 2026.
Key companies related to AstraZeneca Pharma India Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
AstraZeneca Pharma India Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, AstraZeneca Pharma India Limited's market cap moved from $355.75 Million to $ 2.44 Billion, with a yearly change of 20.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹2.44 Billion | -6.42% |
| 2025 | ₹2.61 Billion | +23.60% |
| 2024 | ₹2.11 Billion | +32.68% |
| 2023 | ₹1.59 Billion | +68.33% |
| 2022 | ₹944.20 Million | +6.71% |
| 2021 | ₹884.82 Million | -32.88% |
| 2020 | ₹1.32 Billion | +76.64% |
| 2019 | ₹746.35 Million | +80.36% |
| 2018 | ₹413.81 Million | +24.37% |
| 2017 | ₹332.72 Million | +26.00% |
| 2016 | ₹264.06 Million | -25.77% |
| 2015 | ₹355.75 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of AstraZeneca Pharma India Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.44 Billion USD |
| MoneyControl | $2.44 Billion USD |
| MarketWatch | $2.44 Billion USD |
| marketcap.company | $2.44 Billion USD |
| Reuters | $2.44 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.